Matthew Gilroy is a partner in Weil’s Mergers & Acquisitions practice and is based in New York.
Matthew regularly represents acquirors, targets, boards of directors, special committees, investment banks and investors in complex domestic and cross border M&A (both negotiated and unsolicited) in a broad range of industries, including for clients such as: Eli Lilly and Company; The Kroger Company; Jefferies Financial Group; Sanofi; Willis Towers Watson; Brookfield; JPMorgan; and Centerview Partners.
Matthew also counsels clients on a broad range of corporate, securities and business-related matters, including fiduciary duties, corporate governance, disclosure issues and compliance matters, as well as defensive measures, takeover tactics, proxy fights and other contests for corporate control.
- Willis Towers Watson PLC in its pending $80 billion combination with Aon PLC.
- Transaction Committee of the Board of Directors of Reynolds American Inc. in Reynolds’ $60.6 billion sale to British American Tobacco p.l.c. (BAT) of the 57.8% of Reynolds stock that BAT did not already own.
- IMS Health Holdings, Inc. in its $17.6 billion all-stock merger of equals with Quintiles Transnational Holdings Inc.
- JAB Holding Company, as leader of an investment group, in that group's $13.9 billion take-private of Keurig Green Mountain, Inc.
- Willis Group Holdings plc in its $18 billion merger of equals with Towers Watson & Co.
- Churchill Capital Corp IV, a SPAC sponsored by Churchill Capital Group, in its $11.75 billion take-public merger with Lucid Motors.
- Churchill Capital Corp III, a SPAC sponsored by Churchill Capital Group, in its $5.7 billion merger with MultiPlan, Inc. that has an enterprise value based on the transaction of approximately $11 billion.
- Foley Trasimene Acquisition Corp. II, a SPAC sponsored by Trasimene Capital FT, LP II, in its $9 billion merger with Paysafe Group Holdings Limited (n/k/a Paysafe Limited).
- Brookfield Asset Management Inc. in its approximately $4.8 billion acquisition of a 61.2% stake in Oaktree Capital Group, LLC.
- Brookfield Asset Management Inc. and Brookfield Property Partners L.P. (BPY) in BPY's $14.4 billion acquisition of the approximately 66% of common stock that it did not already own of GGP Inc. (f/k/a General Growth Properties Inc.).
- Eli Lilly and Company in its approximately $8 billion acquisition of Loxo Oncology, Inc.; in its $5.4 billion acquisition of the animal health business of Novartis; in its $1.1 billion acquisition of Dermira, Inc.; in its $1 billion acquisition of Prevail Therapeutics Inc.; in its acquisitions of CoLucid Pharmaceuticals, Inc., ChemGen Corp. and Radiopharmaceuticals; in its sale of veterinary assets to Virbac SA; and in its strategic review of Elanco, its animal health division, concluding with the initial public offering of a minority stake in Elanco.
- Principal shareholders and directors of Skillz Inc. in Skillz's business combination with Flying Eagle Acquisition Corp., a SPAC, in a transaction that implied an equity valuation for Skillz of $3.5 billion.
- G&K Services, Inc. in its $2.2 billion merger with Cintas Corporation.
- Sanofi in its $4.8 billion acquisition of Ablynx NV.
- First Data Corporation in its $760 million acquisition of BluePay, Inc. and in its $750 million acquisition via cash tender offer of CardConnect Corp.
- J.P. Morgan and another major financial institution, as financial advisors to AT&T Inc., in AT&T’s $108.7 billion acquisition of Time Warner Inc.
- Morgan Stanley, as financial advisor to Cigna Corporation, in Cigna's proposed $54.2 billion sale to Anthem Inc.
- Centerview Partners, as financial advisor to Caesars Entertainment Corporation, an owner of Caesars Interactive Entertainment, Inc., in Caesars Interactive’s $4.4 billion sale of Playtika to a consortium led by Shanghai Giant Network Technology Co.
- Brookfield Asset Management Inc. in its $2.8 billion acquisition of all of the outstanding common shares not already owned by Brookfield Property Partners L.P. of Rouse Properties, Inc.
- Progressive Waste Solutions Ltd. in its $2.67 billion merger with Waste Connections, Inc.
- The Kroger Company in the $2.15 billion sale of its convenience store business unit to EG Group; in its $280 million acquisition of Vitacost.com, Inc.; and in its sale of its Turkey Hill business to Peak Rock Capital.
- Leucadia National Corporation in its $3.7 billion merger with Jefferies Group.
- Leucadia National Corporation in its acquisition of National Beef Packing Company for $868 million.
- Providence Equity Partners Inc., Ontario Teachers’ Pension Plan Board and Madison Dearborn Partners, LLC in the proposed $48.5 billion going-private acquisition of BCE Inc. (Bell Canada).
- Yildiz Holding AS in its $850 million acquisition of Godiva Chocolatier Inc.
- ATMI, Inc. in its $1.2 billion sale to Entegris, Inc. and in the sale of its LifeSciences Business to Pall Corporation.
- Lottomatica S.p.A. in its $4.5 billion acquisition of GTECH Holding Corporation.
- Centerview Partners, as financial advisor to the Special Committee of the Board of Directors of Caesars Entertainment Corporation, in its $3.2 billion merger with Caesars Acquisition Company.
- Computershare Ltd. in its sale of Highlands Insurance Solutions, LLC.
- Health Management Associates in its $7.6 billion sale to Community Health Systems.
- American Realty Capital Properties, Inc. in its approximately $700 million sale of Cole Capital to RCS Capital Corp.
- Board of Directors of Herbalife in defense of a position taken in the company by Pershing Square.
- Medicis Pharmaceutical Corporation in its $2.6 billion sale to Valeant Pharmaceuticals International (n/k/a Bausch Health Companies).
- Cedar Fair, L.P. in its proposed $2.4 billion acquisition by an affiliate of Apollo Global Management.
- Irving Place Capital in its $412 million acquisition of Thermadyne Holdings Corporation.
- American International Group, Inc. in its sale of a $16 billion preferred interest in American International Assurance Company to the Federal Reserve Bank of New York.
- American International Group, Inc. in its sale of a $9 billion preferred interest in American Life Insurance Company to the Federal Reserve Bank of New York.
- Cardinal Health, Inc. in the spin-off of its Clinical and Medical Products businesses.
- Macquarie Infrastructure Partners and Macquarie Communications Infrastructure Group in its $1.425 billion acquisition of Global Tower Partners from Blackstone.
- Lone Star Technologies in its $2.1 billion sale to United States Steel Corp.
- Florida Rock Industries Inc. in its $4.6 billion sale to Vulcan Materials Company.
- Omnicare, Inc. in its $490 million hostile acquisition of NCS HealthCare, Inc.
- Houghton Mifflin Riverdeep Group plc in its $4 billion acquisition of the Harcourt US Schools Education business of Reed Elsevier Group plc.
- The Walt Disney Company in its $5.3 billion acquisition of Fox Family Worldwide, Inc.
- The MONY Group in its $2.3 billion sale to AXA Financial.
- LifePoint Hospitals, Inc. in its $1.7 billion sale to Province Healthcare Company.
- PJT Partners Inc. in its approximately $165 million acquisition of CamberView Partners Holdings, LLC.
- Jefferies Financial Group Inc. in its approximately $165 million acquisition of the remaining 30% shareholding interest it didn't already own in HomeFed Corporation.
- Algonquin Power & Utilities Corp, in its $113 million acquisition, via private placement, of an additional stake in Atlantica Sustainable Infrastructure PLC.
Matthew is recognized as a “Highly Regarded” lawyer for M&A by IFLR1000 in the U.S. and has been recognized by Legal 500 and Chambers USA. Matthew was named a 2014 “Rising Star” by Law360 and to The M&A Advisor’s 2013 “40 under 40” list as an emerging leader in his field. Matthew was profiled in Law360’s “Sealing the Deal” for his work advising Medicis in its $2.6 billion sale to Valeant Pharmaceuticals (n/k/a Bausch Health Companies) and was also profiled as a 2013 “MVP” for Health by Law360. He has authored several articles on the fiduciary duties of corporate directors and developments in the mergers and acquisitions area. In 2006, Matthew received a Burton Award for Legal Achievement for his article, “Taking a Hard Look at Poison Pills” (New York Law Journal, November 7, 2005).
Matthew is also part of Weil’s Professional Evaluation & Compensation Committee, and has been active within the profession overall, having represented the Firm on the Corporations Law Committee of the New York City Bar. Matthew is a member of the Board of Visitors of the Georgetown University Law Center and Georgetown’s Corporate Counsel Institute. Matthew is also a member of the Board of Directors of New Alternatives for Children, a charitable organization that provides innovative high quality services in support of birth, foster and adoptive families caring primarily for medically fragile children.